Filters:
Understanding The Circadian Clocks of Individual Cells
UT Southwestern Medical Center
DALLAS - July 2, 2020 - Two new studies led by UT Southwestern scientists outline how individual cells maintain their internal clocks, driven both through heritable and random means. These findings, published online May 1 in PNAS and May 27 in eLife, help explain how organisms' circadian clocks maintain flexibility and could offer insights into aging and cancer.
American Cancer Society awards Research Scholar Grant to Brooke Emerling
Sanford Burnham Prebys Medical Discovery Institute
Sanford Burnham Prebys Medical Discovery Institute is pleased to announce that the American Cancer Society (ACS) has awarded Brooke Emerling, Ph.D., a Research Scholar Grant to study a new approach to targeting tumors that have a mutation in the p53 gene--the most altered gene in human cancers. The grants are often a career-launching award for "rising stars" in the cancer research arena.
Cancer cells make blood vessels drug resistant during chemotherapy
Hokkaido University
Scientists at Hokkaido University and collaborators have identified how inflammatory changes in tumors caused by chemotherapy trigger blood vessel anomalies and thus drug-resistance, resulting in poor prognosis of cancer patients.
Study Shows Breast Cancer Detected Earlier in States with Expanded Medicaid Coverage
Yale Cancer Center
In a new study by Yale Cancer Center, researchers have demonstrated that in states with expanded Medicaid coverage through the Affordable Care Act (ACA) a higher percentage of women with breast cancer had their disease diagnosed at an early stage. No such change was seen in states that didn't expand their coverage. The findings were published today in JAMA Surgery.
Expert in Early Phase Therapeutics Joins NYU Langone Health as Associate Director for Clinical Research at Perlmutter Cancer Center
NYU Langone Health
Janice M. Mehnert, MD, a nationally recognized expert in early phase therapeutics and the treatment of skin malignancies, has been appointed associate director for clinical research at NYU Langone Health's Perlmutter Cancer Center. She assumes her post July 1, 2020.
Epigenetics Researcher Yang Shi Appointed Member of Ludwig Oxford
Ludwig Cancer Research
It is with great pleasure that Ludwig Cancer Research announces the appointment of Yang Shi as Member of the Oxford Branch of the Ludwig Institute for Cancer Research.
NCCN: What People with Cancer and their Caregivers Need to Know about CAR T-Cell Therapy
National Comprehensive Cancer Network(r) (NCCN(r))
The National Comprehensive Cancer Network (NCCN) has published a new NCCN Guidelines for Patients: Immunotherapy Side Effects focused on chimeric antigen receptor (CAR) T-cell therapy. This is book two in a series that includes another book on irAEs focused on immune checkpoint inhibitors.
Number of Hospitalizations Can Be Important Clinical Indicator for Head, Neck Cancer Patients
Roswell Park Comprehensive Cancer Center
Patients who were unexpectedly hospitalized for dehydration, fever or other ailments while undergoing radiation treatment for head and neck cancers were at a higher risk for less favorable outcomes, a new study from Roswell Park Comprehensive Cancer Center reports.
What to Wear to Protect Your Skin From the Sun
American Academy of Dermatology
Skin cancer is the most common cancer in the U.S., and nearly 20 Americans die from melanoma, the deadliest form of skin cancer, every day. As more Americans prepare to head outdoors for the 4th of July holiday, dermatologists from the American Academy of Dermatology have an important reminder: dress to protect yourself from the sun. In addition to seeking shade and applying sunscreen, wearing protective clothing goes a long way in protecting you from the sun's harmful UV rays, which can increase your risk of skin cancer. However, not all clothing is created equal when it comes to sun protection, say dermatologists. Some garments provide better UV protection than others.
School HPV vaccine policies could result in higher vaccination rates, reduction in cancers
University of California, Los Angeles (UCLA), Health Sciences
A UCLA-led study has found that in 2 of 3 states and jurisdictions with policies that require students entering school to receive the human papillomavirus vaccine, vaccination rates among 13-to-17-year-olds were significantly higher than in surrounding states without such policies.
USC Norris Comprehensive Cancer Center receives $5 million for cancer drug discoveries
Keck Medicine of USC
USC Norris Comprehensive Cancer Center receives $5 million for cancer drug discoveries
Study Validates Combination Therapy for Aggressive Endometrial Cancer
Yale Cancer Center
Yale Cancer Center (YCC) scientists have found that combining the targeted drug trastuzumab with chemotherapy significantly improves survival rates for women with a rare, aggressive form of endometrial cancer.
How to Recognize Side-Effects from Immunotherapy? New NCCN Guidelines for Patients can Help
National Comprehensive Cancer Network(r) (NCCN(r))
New NCCN Guidelines for Patients: Immunotherapy Side Effects - Immune Checkpoint Inhibitors from National Comprehensive Cancer Network and NCCN Foundation shares information for patients and caregivers on how to recognize and manage adverse events from immune checkpoint inhibitors.
St. Jude Cloud portal expands access to treasure trove of pediatric solid tumor data
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital develops the Childhood Solid Tumor Network data portal to speed discoveries and novel therapies for treatment of childhood solid tumors
A Study of Early-Onset Colorectal Cancer in Young Adult Men Reveals "Hotspots" of Death in the United States
Huntsman Cancer Institute at the University of Utah
A study led by Charles Rogers, PhD, examines a trend of increasing incidence and mortality among young men diagnosed with colorectal cancer. The authors identify "hotspot" areas of the U.S. where colorectal cancer is on the rise. For men with early-onset colorectal cancer, Black men are more likely to die of the disease than other racial groups.
Poseidon Innovation Announces Funding for Three UC San Diego Researchers
University of California San Diego
UC San Diego and Deerfield Management created Poseidon Innovation to support researchers working to advance disease-curing therapeutics by funding early stage projects and expediting the drug-development cycle. Poseidon announces it is funding three researchers.
Neural network can determine lung cancer severity
National Institute of Biomedical Imaging and Bioengineering
NIBIB-funded researchers at Stanford University have created an artificial neural network that analyzes lung CT scans to provide information about lung cancer severity that can guide treatment options.
Research News Tip Sheet: Story Ideas from Johns Hopkins Medicine
Johns Hopkins Medicine
During the COVID-19 pandemic, Johns Hopkins Medicine Media Relations is focused on disseminating current, accurate and useful information to the public via the media. As part of that effort, we are distributing our "COVID-19 Tip Sheet: Story Ideas from Johns Hopkins" every Tuesday throughout the duration of the outbreak.
Inherited mutation found among Brazilians increases cancer risk
St. Jude Children's Research Hospital
Genomic research helps explain why some people with a common TP53 mutation widespread in Brazil get cancer while others do not.
American Cancer Society Updates Guidelines for Cancer Prevention
Rutgers Cancer Institute of New Jersey
The American Cancer Society recently updated its nutrition and physical activity guidelines for cancer prevention. These updates focus on increasing physical activity and developing healthy eating patterns at every age, with an emphasis on maintaining a healthy body weight through all stages of life.
Houston Methodist oncologist available to comment on NCI model predicting 10,000 additional breast/colorectal cancer deaths due to COVID-19
Houston Methodist
St. Jude creates resource for pediatric brain tumor research
St. Jude Children's Research Hospital
Researchers worldwide can access orthotopic patient-derived xenograft models to speed discovery and test novel therapies for childhood brain tumors.
St. Jude Children's Research Hospital president, CEO recognized for contributions to cancer research
St. Jude Children's Research Hospital
The American Association for Cancer Research honored St. Jude President and CEO James R. Downing, M.D., with its inaugural AACR-St. Baldrick's Foundation Award for Outstanding Achievement in Pediatric Cancer Research.
St. Jude pediatric oncologist Dylan Graetz receives Young Investigator Award from ASCO
St. Jude Children's Research Hospital
Dylan Graetz, M.D., M.P.H., a pediatric hematology-oncology fellow at St. Jude, has received a Young Investigator Award from the American Society of Clinical Oncology.
Immune Cells Infiltrating Tumors May Play Bigger Cancer Role Than Previously Thought
University of California San Diego Health
UC San Diego researchers uncovered in mice how IRE1α, a molecule involved in cells' response to stress, determines whether macrophages promote inflammation in the tumor microenvironment. Inflammation is known to promote tumor growth, making IRE1α an attractive target for drug development.
Focused ultrasound shows promise against deadliest brain tumor
University of Virginia Health System
An innovative use of focused ultrasound is showing promise against glioblastoma, the deadliest brain tumor, and could prove useful against other difficult-to-treat cancers.
Online program significantly improves insomnia in adolescent and young adult cancer survivors, study finds
Dana-Farber Cancer Institute
In a study published today by Pediatric Blood and Cancer, researchers at Dana-Farber Cancer Institute show that an online program developed specifically for AYA cancer survivors can significantly alleviate insomnia and improve overall quality of life.
Early clinical trial supports tumor cell-based vaccine for mantle cell lymphoma
The Rockefeller University Press
A phase I/II clinical trial by researchers at Stanford University suggests that vaccines prepared from a patient's own tumor cells may prevent the incurable blood cancer mantle cell lymphoma (MCL) from returning after treatment. The study, which will be published June 19 in the Journal of Experimental Medicine (JEM), reveals that the vaccines are a safe and effective way to induce the body's immune system to attack any tumor cells that could cause disease relapse.
Breakthrough discovery to transform prostate cancer treatment
University of South Australia
A novel formulation of the prostate cancer drug abiraterone acetate - currently marketed as Zytiga - will dramatically improve the quality of life for people suffering from prostate cancer, as pre-clinical trials by the University of South Australia show the new formulation improves the drug's effectiveness by 40 per cent.
Study shows sedentary behavior independently predicts cancer mortality
University of Texas M. D. Anderson Cancer Center
In the first study to look at objective measures of sedentary behavior and cancer mortality, researchers from The University of Texas MD Anderson Cancer Center found that greater inactivity was independently associated with a higher risk of dying from cancer.
Vitamin D could help mitigate chemotherapy side effects
University of South Australia
New findings by University of South Australia researchers reveal that Vitamin D could potentially mitigate chemotherapy-induced gastrointestinal mucositis and provide relief to cancer patients.
PSA screening affords men long-term benefits, study finds
University of Washington School of Medicine
Prostate cancer researchers and clinicians recommend reconsidering screening guidelines, saying benefits may outweigh potential harms.
COVID-related Delays in Colorectal Cancer Screening Jeopardizes Preventive Care, Early Treatment
Rush University Medical Center
Cancer physicians are concerned that Covid-related delays could reverse important gains in preventing colorectal cancer
Combination biomarker predicts response to immune checkpoint therapy in patients with advanced bladder cancer
University of Texas M. D. Anderson Cancer Center
A combination of two biomarkers was predictive of improved clinical responses and prolonged survival following treatment with immune checkpoint inhibitors in patients with advanced bladder cancers.
Light-Activated 'CRISPR' Triggers Precision Gene Editing and Super-Fast DNA Repair
Johns Hopkins Medicine
In a series of experiments using human cancer cell lines, scientists at Johns Hopkins Medicine say they have successfully used light as a trigger to make precise cuts in genomic material rapidly, using a molecular scalpel known as CRISPR, and observe how specialized cell proteins repair the exact spot where the gene was cut.
Comparable Quality of Life Measures After Robot-Assisted Versus Conventional Surgery for Bladder Cancer
Wolters Kluwer Health: Lippincott Williams and Wilkins
For patients with bladder cancer, health-related quality of life (HRQoL) outcomes are similar after high-tech robot-assisted surgery compared to conventional open surgery, reports The Journal of Urology(r), Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
Common cholesterol drugs could slow spread of breast cancer to brain
University of Notre Dame
A new study from the University of Notre Dame shows drugs used to treat high cholesterol could interfere with the way breast cancer cells adapt to the microenvironment in the brain, preventing the cancer from taking hold.
New Aad Survey: 74% of Parents Today Say They Worry About Sun Protection More with Their Children Than Their Parents Did with Them
American Academy of Dermatology
With Father's Day approaching, dermatologists are giving parents two thumbs up for keeping sun protection top of mind for their families. According to a new survey from the American Academy of Dermatology, 74% of parents today say they worry about sun protection more with their children than their parents did with them, and 90% of parents believe it's important to teach their children healthy habits now so they will keep them when they are adults.
Loss of Lipid-Regulating Gene Fuels Prostate Cancer Spread
Johns Hopkins Medicine
Johns Hopkins Kimmel Cancer Center researchers from the Department of Radiation Oncology and Molecular Radiation Sciences identified a lipid-regulating protein that conveys what the researchers describe as "superpowers" onto prostate cancer cells, causing them to aggressively spread.
NCCN Works to Improve Global Cancer Care for Children with Newly Translated Recommendations
National Comprehensive Cancer Network(r) (NCCN(r))
NCCN Guidelines for Pediatric Acute Lymphoblastic Leukemia (ALL) in Chinese, Japanese, French, Spanish, and Portuguese are now available for free at NCCN.org
Cancer Care Can't Wait
Rutgers Cancer Institute of New Jersey
Many people are worried about things in their lives that have been put on hold. For some women, this includes an annual mammogram. Safeguards have been put in place at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health facilities so women can safely continue to get this potentially life-saving screening or any follow-up care that may be needed.
UCI Researchers Uncover Cancer Cell Vulnerabilities; May Lead to Better Cancer Therapies
University of California, Irvine
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.
Putting "Super" in Natural Killer Cells
University of California San Diego Health
Using induced pluripotent stem cells (iPSCs) and deleting a key gene, researchers at University of California San Diego School of Medicine have created natural killer cells -- a type of immune cell -- with measurably stronger activity against a form of leukemia, both in vivo and in vitro.
Research News Tip Sheet: Story Ideas from Johns Hopkins Medicine
Johns Hopkins Medicine
Research news from Johns Hopkins Medicine.
Breaking Research News from Annual Meeting of American Society of Clinical Oncology
Johns Hopkins Medicine
Johns Hopkins Kimmel Cancer Center thoracic cancer and cancer genomics experts reported promising new findings and studies in mesothelioma, lung cancer and melanoma at the annual meeting of the American Society of Clinical Oncology (ASCO), the world's leading professional organization for physicians and oncology professionals caring for cancer patients.
Cellular Stress Causes Cancer Cell Chemoresistance
University of Vienna
Postgenomic technologies reveal new mechanism of stress-induced chemoresistanceResistance of cancer cells against therapeutic agents is a major cause of treatment failure, especially in recurrent diseases. An international team around the biochemists Robert Ahrends from the University of Vienna and Jan Medenbach from the University of Regensburg identified a novel mechanism of chemoresistance which has now been published in "Nature Communications".
Cancer Researchers Have a Head Start in Fight Against COVID-19
Roswell Park Comprehensive Cancer Center
Researchers at Roswell Park Comprehensive Cancer Center have been actively engaged in the effort to develop treatments or other control strategies that can help communities worldwide to address the impacts of the COVID-19 pandemic.
Study: Mixed Progress in Efforts to Reduce Low Value Breast Cancer Surgery
Michigan Medicine - University of Michigan
A U-M review found national Choosing Wisely recommendations to reduce overtreatment in early stage breast cancer weren't consistently followed.
Predicting Cancer Behavior Requires Better Understanding of Tumor Cells
American Institute of Physics (AIP)
Our ability to predict who will get cancer, how patients will respond to treatment, or if patients will relapse is still quite limited, despite advances in the detection of genetic mutations and the establishment of risk factors; recently researchers were inspired to find new ways of looking at the problem. In Biomicrofluidics, they report that using cellular mechanophenotyping, along with traditional methods such as immunostaining and genetic analysis, may provide a more comprehensive view of a tumor.
Yale Scientists Develop a New Experimental Method to Study Infection and Disease, Including COVID-19
Yale Cancer Center
Yale Cancer Center scientists have developed a new cell screening method for agents that alter biologic functions. This approach uses thousands of artificial proteins called "traptamers" and may help to answer research questions that are difficult to address with other cell screening methods, including the SARS-CoV-2 virus, COVID-19. The data is published today in the journal Cell Reports.
Chemotherapy and Cancer Gang up to Cause a Neurological Side Effect, Study Says
Georgia Institute of Technology
Chemotherapy has been the lone suspect in a neurological ailment, but cancer also appears to be to blame. The havoc they wreak together is much more than additive.
Preventing pancreatic cancer metastasis by keeping cells "sheltered in place"
Sanford Burnham Prebys Medical Discovery Institute
Scientists at Sanford Burnham Prebys Medical Discovery Institute have shown that pancreatic cancer metastasis--when tumor cells gain the deadly ability to migrate to new parts of the body--can be suppressed by inhibiting a protein called Slug that regulates cell movement. The study, published in the Journal of Experimental Medicine, also revealed two druggable targets that interact with Slug and hold promise as treatments that may stop the spread of pancreatic cancer.
JNCCN: Many Hospitalized People with Advanced Cancer Struggle with Important Daily Tasks
National Comprehensive Cancer Network(r) (NCCN(r))
New research from Mass General Cancer Center, published in the June 2020 issue of JNCCN--Journal of the National Comprehensive Cancer Network, found 40.2% of hospitalized patients with advanced, incurable cancer were functionally impaired at the time of admission.
Cancer Care Can't Wait
Rutgers Cancer Institute of New Jersey
Cancer patients might still have heightened concerns over rescheduling a postponed surgery or scheduling a new surgery right now due to COVID-19. Rutgers Cancer Institute of New Jersey expert explains how surgical care precautions have been instituted to ensure the safety of patients and medical staff.
Identifying survivors at high risk of secondary cancers
St. Jude Children's Research Hospital
St. Jude researchers look at the combined effect of cancer treatments and inherited mutations in DNA-repair genes.
FIRE-SCLC analysis: Largest ever study of first-line radiosurgery for brain metastases from small cell lung cancer
University of Colorado Cancer Center
The international First-line Radiosurgery for Small-Cell Lung Cancer (FIRE-SCLC) analysis led by University of Colorado Cancer Center researchers and published today in JAMA Oncology shows no overall survival benefit from whole-brain radiation compared with radiosurgery in patients with small cell lung cancer.
Memorial Sloan Kettering - Hackensack Meridian Health Partnership Announces Funding for Inaugural Immunology Research Collaboration Projects
Hackensack Meridian Health
As part of the Memorial Sloan Kettering - Hackensack Meridian Health Partnership, the two organizations have formed an Immunology Research Collaboration. Through this joint initiative, researchers can apply for funding to support innovative investigations to explore the power of the immune system and ways it may be harnessed to fight cancer.
Some types of prostate cancer may not be as aggressive as originally thought
University of California, Los Angeles (UCLA), Health Sciences
Researchers at the UCLA Jonsson Comprehensive Cancer Center analyzed gene-expression patterns in the most aggressive prostate cancer grade group -- known as Gleason grade group 5 -- and found that this grade of cancer can actually be subdivided into four subtypes with distinct differences. The findings may affect how people are treated for the disease.
MD Anderson and Rakuten Medical announce strategic alliance to advance Illuminox platform for cancer treatments
University of Texas M. D. Anderson Cancer Center
The University of Texas MD Anderson Cancer Center and Rakuten Medical, Inc. today announced a strategic alliance collaboration agreement to advance the development of new cancer therapies based on Rakuten Medical's proprietary IlluminoxTM technology platform.
Continued nicotine use promotes brain tumors in lung cancer patients, Wake Forest study suggests
The Rockefeller University Press
Researchers at Wake Forest School of Medicine have discovered that nicotine promotes the spread of lung cancer cells into the brain, where they can form deadly metastatic tumors. The study, which will be published June 4 in the Journal of Experimental Medicine (JEM), suggests that nicotine replacement therapies may not be suitable strategies for lung cancer patients attempting to quit smoking. In addition, the researchers show that the naturally occurring drug parthenolide blocks nicotine-induced brain metastasis in mice, suggesting a potential therapeutic option in humans.
Study shows how to achieve optimal treatment and improve outcomes for rare cancer patients
Mercy Medical Center
Scientists Reveal How Mutations in Metabolism Can Drive Cancers
Yale Cancer Center
Yale Cancer Center scientists have identified mutations in metabolite-producing genes as a disruption of DNA repair. These mutation-driven "oncometabolites" may make cells more prone to developing cancer--but also more vulnerable to new cancer treatment strategies.
UK, ArtemiLife Partner to Test for Anti-Cancer Activity of Artemisia Annua Extracts
University of Kentucky
The University of Kentucky and ArtemiLife Inc. will collaborate on a clinical study using the extract of a medicinal plant grown in Kentucky to test for anti-cancer activity of Artemisia annua and to determine the recommended dose of Artemisia annua for future clinical trials.
UK Study Finds Many Colon Cancer Patients Not Receiving Standard of Care Therapy
University of Kentucky
A new University of Kentucky Markey Cancer Center study finds that many Kentucky patients with colon cancer are not receiving the recommended standard of care therapy for their disease.
New technique takes 3D imaging an octave higher
Colorado State University
A collaboration between Colorado State University and University of Illinois at Urbana-Champaign resulted in a new, 3D imaging technique to visualize tissues and other biological samples on a microscopic scale, with potential to assist with cancer or other disease diagnoses.
Bacteria in Cancer Cells May Help or Hinder Treatment
Weizmann Institute of Science
Weizmann Institute scientists show that bacteria live inside all cancer cells, from brain to breast to bone, and that each type of cancer has its own type of bacteria. Understanding this relationship could help predict treatment effectiveness or lead to ways of using the bacteria to boost treatments.
Swelling of Tissues Drives Immune System Activity, UCLA Researchers Find
University of California, Los Angeles (UCLA), Health Sciences
A UCLA research team has identified a new paradigm for understanding the regulation of the immune system, potentially paving the way for new approaches to treating infections and immune-related diseases such as type 1 diabetes and certain cancers.
Researchers Identify a Moving Target in Small Cell Lung Tumors
Huntsman Cancer Institute at the University of Utah
About 15 percent of lung cancers are classified as small cell lung cancer. Recent studies have indicated that four major subtypes of small cell lung cancer exist, yet approaches to tailor treatment of these subtypes have not yet become standard of care. Today in the journal Cancer Cell, scientists outline new findings about the origins of these lung cancer subtypes, paving the way for a new foundation to study this disease.
Eighth Annual Cancer Immunotherapy Month(tm) in June Celebrates Progress in Treatment and Advances in Research
Cancer Research Institute
June is Cancer Immunotherapy Month, a 30-day awareness campaign started by the Cancer Research Institute eight years ago to educate, inform, and inspire the global community of patients, caregivers, scientists, donors, and other cancer-concerned individuals and organizations.
Your Cancer Care is too Important to Wait
Rutgers Cancer Institute of New Jersey
Minimizing your exposure to COVID-19 doesn't require sacrificing cancer care or preventive services. Rutgers Cancer Institute of New Jersey and RWJBarnabas Health are taking extra precautions to ensure that patients can continue to receive exceptional care close to home.
Study Shows Promise for Non-Small Cell Lung Cancer Patients Who Require New Treatment Options
Atlantic Health System
A new type of immunotherapy treatment for metastatic non-small cell lung cancer (NSCLC) is being tested by Missak Haigentz, Jr., MD, medical director of hematology and oncology for Atlantic Health System. Early results appear promising in this phase 1/2 clinical trial of ADXS-503 being developed by Advaxis, Inc., a new type of cancer therapy which targets "hotspot" mutations that commonly occur in specific cancer types, both by itself and in combination with immunotherapy Keytruda(r) (pembrolizumab), which is commonly used to treat this type of lung cancer. Dr. Haigentz and colleagues published early results of this study in conjunction with ASCO 2020, the world's premier scientific meeting for clinical research in oncology.
Building an International Consortium to Enhance Decision Making in Hodgkin Lymphoma
Rutgers Cancer Institute of New Jersey
Findings and the development of a new international consortium known as HoLISTIC are being shared as part of a poster presentation at the virtual 2020 American Society for Clinical Oncology Annual Meeting taking place this week.
Decisions to Stray From Clinical Oncology Pathways Are Often Justified, Roswell Park Analysis Shows
Roswell Park Comprehensive Cancer Center
Clinical oncology pathways are an important tool, helping cancer care providers and their patients to zero in on the most appropriate care plan. But a treating professional's decision to depart from the recommendations of these decision-support resources may be well-founded and in the patient's best interests, a new Roswell Park study shows.
Targeted Drugs and Immunotherapies May Lower Risk of Therapy-Related Hematologic Cancers
Roswell Park Comprehensive Cancer Center
While breakthrough treatments have emerged for several cancers over the last two decades, driving striking improvements in survival and other clinical outcomes, too little is known about the risk of therapy-related hematologic cancers following targeted and immunotherapeutic approaches. In a study to be presented at the American Society of Clinical Oncology (ASCO) 2020 virtual meeting, a Roswell Park Comprehensive Cancer Center team reports that in many cases, these newer treatment approaches may reduce the risk of therapy-related myelodysplastic syndrome or acute myeloid leukemia (tMDS/AML) compared to chemotherapy-based treatment strategies.
Study reveals factors influencing outcomes in advanced kidney cancer treated with immunotherapy
Dana-Farber Cancer Institute
By analyzing tumors from patients treated with immunotherapy for advanced kidney cancer in three clinical trials, Dana-Farber Cancer Institute scientists have identified several features of the tumors that influence their response to immune checkpoint inhibitor drugs.
Targeted therapy tepotinib for non-small cell lung cancer with MET exon 14 skipping mutation shows durable response
University of Texas M. D. Anderson Cancer Center
Patients with advanced non-small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping mutation had a 46.5% objective response rate to the targeted therapy drug tepotinib, as shown in a study published today in the New England Journal of Medicine and presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 9556 - Poster 322) by researchers from The University of Texas MD Anderson Cancer Center.
Targeted therapy pralsetinib achieves high response rates in advanced cancers with RET gene fusions
University of Texas M. D. Anderson Cancer Center
The targeted therapy pralsetinib appears to have high response rates and durable activity in patients with a broad variety of tumors harboring RET gene fusions, according to results from the international Phase I/II ARROW trial, led by researchers at The University of Texas MD Anderson Cancer Center.
Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4 shows early activity in patients with advanced solid tumors
University of Texas M. D. Anderson Cancer Center
The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4 cancer antigen, achieved responses in patients with multiple solid tumor types, including synovial sarcoma, head and neck cancer and lung cancer, according to results from a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
Huntsman Cancer Institute Researchers Demonstrate Better Outcomes, Lower Cost in First-Ever Oncology Hospital-at-Home Evaluation
Huntsman Cancer Institute at the University of Utah
Researchers at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) presented the first outcomes evaluation of an adult oncology hospital-at-home program today at the 2020 American Society of Clinical Oncology (ASCO) annual meeting. The study evaluated patients participating in HCI's Huntsman at Home. The data demonstrate strong evidence for this care model, showing improved patient outcomes, including reduced hospitalizations and decreased visits to the emergency department.
Study Shows Clinical Evidence of Anti-Tumor Activity in Patients with Metastatic Castration-Resistant Prostate Cancer
Yale Cancer Center
Results of a Phase I clinical trial conducted by researchers at the Yale Cancer Center have shown that ARV-110, an androgen receptor PROTAC(r) protein degrader, demonstrates anti-tumor responses in patients with metastatic castration-resistant prostate cancer.
Atlantic Health System Leads Phase 1 Study on CPI-613(r) (Devimistat), First-in-Class Treatment for Pancreatic Cancer to be Presented at American Society of Clinical Oncology (ASCO) 2020
Atlantic Health System
Dr. Alistar has pioneered the use of CPI-613(r) (devimistat), a unique first-in-class treatment for locally advanced or metastatic pancreatic cancer, in combination with two chemotherapy drugs. Devimistat uniquely targets enzymes involved in cancer cell metabolism, against pancreatic cancer. The study's efficacy data suggest devimistat has synergy with chemotherapy.The current study was funded by the drug's manufacturer, New Jersey-based Rafael Pharmaceuticals and by Atlantic Health System.
Study Shows Profound Benefit with Targeted Therapy for Patients with Early Stage NSCLC
Yale Cancer Center
According to findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery significantly improves disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations.
Research News Tip Sheet: Story Ideas From Johns Hopkins
Johns Hopkins Medicine
During the COVID-19 pandemic, Johns Hopkins Medicine Media Relations is focused on disseminating current, accurate and useful information to the public via the media. As part of that effort, we are distributing our "COVID-19 Tip Sheet: Story Ideas from Johns Hopkins" every Tuesday throughout the duration of the outbreak.
Ludwig Lausanne Study Charts the Immune Landscape of Multiple Brain Cancers
Ludwig Cancer Research
A Ludwig Cancer Research study has profiled, in a sweeping comparative analysis, the distinct immune landscapes of tumors that arise in the brain, or gliomas, and those that metastasize to the organ from the lungs, breast and skin.
MSK: Cancer Isn't Sheltering in Place
Memorial Sloan Kettering Cancer Center
As the height of the COVID-19 outbreak in New York City and the Tri-State area begins to subside, Memorial Sloan Kettering Cancer Center oncologists are urging patients to schedule cancer screenings and treatments now - as the long-term toll of missed diagnoses and delayed treatments could be devastating for patients and their loved ones across the region and the country.
Colorado tool, My-DST, may pick best multiple myeloma treatment
University of Colorado Cancer Center
University of Colorado Cancer Center team uses liquid biopsy to predict multiple myeloma drug resistance and sensitivity.
New drug combinations help overcome resistance to immunotherapy
University of California, Los Angeles (UCLA), Health Sciences
A new study from researchers at the UCLA Jonsson Comprehensive Cancer Center helps explain how disruptions in genes can lead to the resistance to one of the leading immunotherapies, PD-1 blockade, and how new drug combinations could help overcome resistance to the anti-PD-1 therapy in a mechanistically-based way.
Combination therapy well-tolerated and highly effective for patients with IDH1-mutated acute myeloid leukemia (AML)
University of Texas M. D. Anderson Cancer Center
A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be effective against a specific genetic subtype of acute myeloid leukemia (AML) in a Phase Ib/II trial led by researchers at The University of Texas MD Anderson Cancer Center. The results of this trial may support a novel course of action for patients with AML harboring an IDH1 mutation who have historically had few treatment options.
Novel targeted drug induced positive response for patients with von Hippel-Lindau disease-associated kidney cancer
University of Texas M. D. Anderson Cancer Center
In an international trial led by researchers at The University of Texas MD Anderson Cancer Center, treatment with MK-6482, the small molecule inhibitor of hypoxia-inducible factor (HIF)-2a was well tolerated and resulted in clinical responses for patients with von Hippel-Lindau disease (VHL)-associated renal cell carcinoma (RCC).
Rutgers Cancer Institute of New Jersey Chair of Radiation Oncology and Associate Vice Chancellor of Cancer Programs Receives Prestigious National Award
Rutgers Cancer Institute of New Jersey
Bruce G. Haffty, MD, associate vice chancellor for cancer programs and chair, radiation oncology at Rutgers Cancer Institute of New Jersey has been selected as the 2020 Gold Medal Award winner by the American Society for Radiation Oncology (ASTRO), a prestigious national award recognizing individuals who have made outstanding lifetime contributions in the field of radiation oncology.
Treatment shows promise in treating deadly brain cancer
McMaster University
In this study, researchers investigated if specific targeting of CD133+ glioblastoma with cutting-edge immunotherapy drugs could eradicate the most aggressive subpopulation of cells in the tumour. They also looked at the safety of CD133-targeting therapies on normal, non-cancerous human stem cells including hematopoietic stem cells which create blood cells and progenitor cells which can form one or more kinds of cells.
Phyllis F. Cantor Center for Research in Nursing and Patient Care Services awarded two major research grants
Dana-Farber Cancer Institute
Nurse-scientists from the Phyllis F. Cantor Center for Research in Nursing and Patient Care Services at Dana-Farber Cancer Institute received more than $1.3 million dollars in funding for two separate research projects.
New Information from NCCN on Overcoming Challenges for People with Head and Neck Cancers
National Comprehensive Cancer Network(r) (NCCN(r))
Newly-completed series of patient guidelines from National Comprehensive Cancer Network (NCCN) shares expert advice with patients and caregivers on treatment and prevention for most common head and neck cancers, including some that are HPV-related.
App Calculates Risk of Delaying Cancer Care During Pandemic
Michigan Medicine - University of Michigan
Data scientists and cancer doctors at the University of Michigan have developed OncCOVID, an app that draws on global cancer and coronavirus data to create individualized mortality risk assessments for receiving immediate versus delayed cancer treatment.
Scientists identify obscure protein responsible for advanced breast cancer
University of South Australia
South Australian scientists have made a critical breakthrough, discovering how an obscure protein causes breast cancer to develop and grow more quickly.
Researchers identify therapeutic targets to prevent cancer-associated muscle loss
The Rockefeller University Press
Researchers at the University of Nebraska Medical Center have identified a key cell signaling pathway that drives the devastating muscle loss, or cachexia, suffered by many cancer patients. The study, which will be published May 22 in the Journal of Experimental Medicine, suggests that targeting this pathway with a drug already in phase 2 clinical trials for diabetes could prevent this syndrome.
Markey Announces Hull as New Associate Director of Population Science and Community Impact
University of Kentucky
The University of Kentucky Markey Cancer Center announces that medical sociologist Pamela Hull, Ph.D., will join the center and serve as its associate director of population science and community impact. She will also serve as the William Stamps Farish Endowed Chair in Cancer Research and join the UK College of Medicine as an associate professor of behavioral science.
Some patients with bladder cancer 'can't wait' for treatment during the COVID-19 pandemic
IOS Press
Bladder cancer is associated with significant illness and mortality, particularly if treatment is delayed. Writing in the journal Bladder Cancer, researchers have outlined recommendations for treatment of both muscle invasive (MIBC) and non-muscle invasive (NMIBC) bladder cancer during the COVID-19 pandemic based on data from trials and prior studies, and taking into account the current strains on the healthcare system.
Next-gen nano technologies to tackle infection and diagnose disease
University of South Australia
Next-gen nano technologies that can prevent infection and diagnose disease are set to transform the medical industry as this important UniSA research is awarded more than $2 million dollars under the National Health and Medical Research Council (NHMRC) 2021 Investigator Grants.
NCCN Foundation Awards Leading Young Investigators Advancing Cancer Research for Adults and Children
National Comprehensive Cancer Network(r) (NCCN(r))
NCCN and the NCCN Foundation announce five new recipients for the 10th annual NCCN Foundation Young Investigator Awards (YIA) Program, overseen by the NCCN Oncology Research Program (ORP)